Do Diana V, Bressler Susan B, Cassard Sandra D, Gower Emily W, Tabandeh Homayoun, Jefferys Joan L, Bressler Neil M
*Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska; †Division of Retina, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; ‡Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; §Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina; and ¶Retina Vitreous Associates Medical Group, Los Angeles, California.
Retina. 2014 Oct;34(10):2063-71. doi: 10.1097/IAE.0000000000000203.
To evaluate the effects of 0.3 mg or 0.5 mg of ranibizumab in eyes with macular telangiectasia type 2 without subretinal neovascularization.
Ten eyes were randomized to either 0.3 mg or 0.5 mg ranibizumab group in 1 eye only. Study eye received ranibizumab at baseline and at Months 1 and 2. Injections at Months 3, 4, and 5 were at investigator's discretion. Participants were followed monthly through 6 months with best-corrected visual acuity, fluorescein angiography, and optical coherence tomography.
For study eyes at baseline, median best-corrected visual acuity letter score was 60 (20/64 Snellen equivalent) and central subfield retinal thickness was 181.5 μm. Median number of injections was six. Median change in best-corrected visual acuity at Month 3 was 4 letters (range: -5 to 9 letters) at both doses in the study eye and 3 letters (range: -10 to 5 letters) in the untreated fellow eye. At Month 3, retinal leakage decreased 0.87 disk area and 0.76 disk area for 0.3 mg and 0.5 mg ranibizumab, respectively. Median change in central subfield retinal thickness was 1 μm and -11 µm for 0.3 mg and 0.5 mg ranibizumab, respectively.
Ranibizumab (0.3 mg or 0.5 mg) decreases leakage secondary to macular telangiectasia type 2, but accompanying improvements in best-corrected visual acuity appear similar to improvements in the untreated fellow eye where retinal thickness is relatively unchanged.
评估0.3毫克或0.5毫克雷珠单抗对2型黄斑毛细血管扩张且无视网膜下新生血管形成的眼睛的疗效。
10只眼睛仅单眼随机分为0.3毫克或0.5毫克雷珠单抗组。研究眼在基线、第1个月和第2个月接受雷珠单抗注射。第3、4和5个月的注射由研究者决定。参与者每月随访6个月，检查最佳矫正视力、荧光素血管造影和光学相干断层扫描。
研究眼在基线时，最佳矫正视力字母评分中位数为60（相当于20/64 Snellen视力），中心子野视网膜厚度为181.5微米。注射次数中位数为6次。研究眼中，两种剂量在第3个月时最佳矫正视力的中位数变化均为4个字母（范围：-5至9个字母），未治疗的对侧眼为3个字母（范围：-10至5个字母）。在第3个月时，0.3毫克和0.5毫克雷珠单抗治疗的视网膜渗漏分别减少0.87视盘面积和0.76视盘面积。0.3毫克和0.5毫克雷珠单抗治疗的中心子野视网膜厚度中位数变化分别为1微米和-11微米。
雷珠单抗（0.3毫克或0.5毫克）可减少2型黄斑毛细血管扩张引起的渗漏，但最佳矫正视力的改善与未治疗的对侧眼相似，后者视网膜厚度相对未变。
